Before, we told you to delete your data because 23andMe was about to be sold. Now, a buyer has been announced, and they’re ...

Durham-based Atsena Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for ATSN-201, its gene therapy product for the ...

Beyond the heart, the study hints that other transplantable organs could benefit from improved cold storage methods using a simple diuretic.

Apellis Pharmaceuticals focuses on creating medicines targeting eye diseases and rare neurological diseases. Read why I rate ...

Pacibekitug, an antibody targeting interleukin-6, hit the primary endpoint in the phase 2 Tranquility trial by sharply ...

A Philadelphia entrepreneur developing eye repair tech stood out among international contenders as it gears up to raise a ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

World made its official U.S. debut, allowing people to scan their eyes in Los Angeles, San Francsico, Austin, Atlanta ...

SHANGHAI - Swiss pharmaceutical giant Roche has announced plans to invest 2.04 billion yuan ($283 million) in building a new ...

The company discontinued development last month of its most mature asset, RLYB212, following disappointing mid-stage ...

Beam Therapeutics Inc.’s BEAM share price has surged by 7.36%, which has investors questioning if this is right time to sell.